Abstract
Background Head-to-head comparisons of high-efficacy therapies for relapsing-remitting multiple sclerosis (RRMS) are lacking. We emulated a target trial to compare the long-term effectiveness of rituximab and cladribine.
Methods We estimated the effect of initiating treatment with rituximab or cladribine by emulating a target trial using data from the Norwegian MS Registry and Biobank at two university hospitals with different treatment strategies. Cumulative incidence and risk differences after 4 years were estimated using a weighted Kaplan-Meier estimator, adjusted for baseline covariates. The primary outcome was MRI disease activity, with the secondary outcomes including relapses and safety.
Results The study included 285 patients, 159 receiving rituximab and 126 receiving cladribine, with a median follow-up of 4.5 years (IQR 4.0 to 5.0). Rituximab-treated patients had a lower risk of new MRI disease activity compared to cladribine-treated patients (p < 0.0001). The 4-year risk was 18% (95% CI 11 to 23) for the rituximab-treated patients and 57% (95% CI 48 to 65) for cladribine-treated patients, yielding a risk difference (RD) of 38 percentage-points (95% CI 29 to 51). The 4-year RD for relapse was 11.2 percentage-points (95% CI 3 to 18) and the RD for discontinuation or a third dose of cladribine was 13.7 percentage-points (95% CI 9 to 25). The incidence of hospitalizations related to potential adverse events was 6.0 per 100 person-years for rituximab and 4.1 per 100 person-years for cladribine.
Conclusions These findings suggest that rituximab has superior effectiveness compared to cladribine during a median follow-up of 4.5 years.
Competing Interest Statement
Drs Rod, Bjornevik, Gran, Overas and Nygaard report no disclosures. Dr Hogestol reports lecture fees from Biogen, Merck and Sanofi-Genzyme and served on scientific advisory boards for Sanofi-Genzyme. He has received unrestricted grant for salary to Oslo University Hospital from Merck. Dr Torkildsen has received speaker honoraria from and served on scientific advisory boards for Biogen, Sanofi-Aventis, Teva, Merck, and Novartis. Dr Konig reports receiving speaker honoraria from Novartis, Biogen, Merck, and Sanofi outside the submitted work. Dr G. Celius has participated in advisory boards and received speaker honoraria from Biogen, Janssen, Merck, Novartis, Teva, Roche, Sanofi, and Bristol Myers Squibb. Dr Myhr has received speaker honoraria from Biogen, Sanofi and Novartis; and honoraria for participation in scientific advisory board from Alexion, and has participated in clinical trials organized by Biogen, Merck, Novartis, Otivio, Sanofi and Roche. Dr Wergeland has received honoraria for serving on advisory boards for Biogen, Janssen, and Sanofi, and speaker fees from Biogen, Janssen, and Sanofi. He has served as Principal Investigator for projects or received unrestricted research support from Biogen.
Funding Statement
Funding BER is funded by the Dam Foundation (2021/FO347349), The Norwegian Multiple Sclerosis Society, and Neuro-SysMed by Grants from The Research Council of Norway, project number 288164. This project was supported in by the Norwegian Multiple Sclerosis Society and Torbjorg Hauges fund. Role of the funders: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The approval was granted by the Norwegian Regional Committee for Medical Research Ethics South-East D. The approval was signed by the leader of the committee, Professor Emeritus of Medicine (Dr. med) Pål Aukrust. The committee approved the project on September 5, 2023 (REK no 629865). All patients had provided written informed consent to participate in the NMSRB for research purposes. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines for cohort studies were followed in the reporting of this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
